98%
921
2 minutes
20
Introduction: Clarithromycin resistance is a crucial factor in the eradication of Helicobacter pylori. This study aimed to evaluate the performance of MmaxSure™ H. pylori & ClaR Assay (MmaxSure™) in the diagnosis and detection of clarithromycin resistance in H. pylori.
Methods: Subjects who underwent esophagogastroduodenoscopy between April 2020 and October 2022 were enrolled. The diagnostic performances of MmaxSure™ and dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) were compared with the rapid urease test and culture. Secondary gene sequencing analysis was performed in discordant cases of PCR tests.
Results: A total of 156 gastric biopsy samples were analyzed. In H. pylori detection, MmaxSure™ showed a 95.9% sensitivity (95% CI: 90.6-98.6), a 42.7% specificity (95% CI: 26.3-60.7), and a kappa value of 0.457. For the detection of A2143G mutation samples, MmaxSure™ showed a 91.2% sensitivity (95% CI: 76.3-98.1), a 93.4% specificity (95% CI: 87.5-97.1), and a kappa value of 0.804. There were a total of 10 discordant cases compared to gene sequencing in A2143G mutation detection for MmaxSure™.
Conclusion: In this study, MmaxSure™ showed comparable diagnostic performance to DPO-PCR in the detection of the H. pylori and A2143G mutation. Further research is needed to confirm the clinical effectiveness of the MmaxSure™ assay in H. pylori eradication.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250404 | PMC |
http://dx.doi.org/10.1159/000538655 | DOI Listing |
Microbiol Spectr
September 2025
Department of Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
complex (MABC) is notoriously difficult to treat. Current guidelines suggest a 14-day-long incubation and/or sequencing of to detect inducible macrolide resistance. We assessed whether the evolution of minimum inhibitory concentrations (MICs) can reliably predict inducible macrolide resistance and clinical outcomes of extrapulmonary MABC infections.
View Article and Find Full Text PDFPhytomedicine
August 2025
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China. Electronic address:
Background: Previous studies have shown that coptisine (COP), a benzyl tetrahydroisoquinoline alkaloid isolated from Coptis chinensis, exhibits antibacterial activity against H. pylori. Furthermore, COP shows a low tendency to induce resistance, suggesting its potential as a therapeutic candidate for H.
View Article and Find Full Text PDFWorld J Gastroenterol
August 2025
Guangxi Zhuang Autonomous Region Engineering Research Center of Clinical Prevention and Control Technology and Leading Drug for Microorganisms with Drug Resistance in Border Ethnic Areas, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China.
Background: (), a globally prevalent pathogen, is exhibiting increasing rates of antimicrobial resistance. However, clinical implementation of pre-treatment susceptibility testing remains limited due to the organism's fastidious growth requirements and prolonged culture time.
Aim: To propose a novel detection method utilizing antibiotic-supplemented media to inhibit susceptible strains, while resistant isolates were identified through urease-mediated hydrolysis of urea, inducing a phenol red color change for visual confirmation.
IJID Reg
September 2025
Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan.
Objectives: Nontuberculous mycobacteria (NTM) are an increasing cause of extrapulmonary infections affecting skin and soft tissue. This study aimed to determine the involvement of NTM in persistent surgical site infections (SSIs) in Bangladesh.
Methods: Specimens of SSIs (wound swab, pus, sinus discharge) were collected from patients who attended a tertiary care hospital during a 6-month period in 2024.
Microbiol Spectr
September 2025
Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, affiliated Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Unlabelled: The complex (MABC) is highly resistant to antibiotics, making the pulmonary disease it causes, known as MABC-PD, difficult to treat. Macrolide antibiotics are the main treatment for MABC-PD, but there is ongoing debate about whether to favor azithromycin (AZI) or clarithromycin (CLA). We compared how well AZI and CLA work against MABC and monitored the risk of developing resistance.
View Article and Find Full Text PDF